Prelude Therapeutics
Price & Volume
Stats
See moreOpen | $2.74 |
Previous Close | $2.76 |
Day Range | $2.63-$2.78 |
52W Range | $0.61-$4.22 |
Market Cap | $173.5M |
Shares Short | 2M |
Financials
See moreRevenue (12 Mos) | $10.5M |
Revenue Growth (YoY) | 116.7% |
Gross Profit (12 Mos) | $10.5M |
Diluted EPS | -$1.47 |
News
See moreYahoo Finance • 3 months ago
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
Yahoo Finance • 3 months ago
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
Yahoo Finance • 3 months ago
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
Yahoo Finance • 3 months ago
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
About
CEO | Dr. Krishna Vaddi D.V.M., Ph.D. |
CFO | Mr. Bryant David Lim J.D. |
Address | 175 Innovation Boulevard, Wilmington, DE, United States, 19805 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 131 |
